Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Therapeutics (LENZ) Stock Price & Analysis
120 Followers
LENZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.51 - $24.59
Previous Close$16.35
Volume168.85K
Average Volume (3M)122.47K
Market Cap
$417.47M
Enterprise Value$233.58M
Total Cash (Recent Filing)$184.26M
Total Debt (Recent Filing)$362.00K
Price to Earnings (P/E)-1.1
Beta0.65
Next Earnings
May 08, 2024EPS Estimate
-$0.82Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-15.34
Shares Outstanding25,534,458
10 Day Avg. Volume183,534
30 Day Avg. Volume122,470
Standard Deviation0.22
R-Squared0.01
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.38
Forecast
1Y Price Target
$34.00Price Target Upside107.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
LENZ Therapeutics News
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageLNZ100/101 are positioned to outperform the competitor Vuity due to a better clinical profile, offering advantages to a broader presbyobia patient population.
Market OpportunityThe presbyopia market represents a significant opportunity with a high unmet need for an effective eyedrop treatment.
Product DevelopmentLenz reported numbers showing everything remains on track for NDA submission of LNZ100 for presbyopia.
Bears Say
Market CompetitionThere are multiple marketed/late-stage competitors that could take presbyopia market share.
Market PerceptionLenz will have to overcome negative perceptions of presbyopia eye drops.
Professional AcceptanceLenz faces the challenge of overcoming negative perceptions of presbyopia eye drops among patients and eyecare professionals.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $9.51 and its highest was $24.59 in the past 12 months.
What is LENZ Therapeutics’s market cap?
Currently, no data Available
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is May 08, 2024 which is 11 days ago.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Mar 18, 2024. The company reported -$2.766 earnings per share for the quarter, missing the consensus estimate of -$0.905 by -$1.861.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Notavailable dividend of $1.03 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -$0.82.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 25,533,533 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$2.766 in its last earnings report, missing expectations of -$0.905. Following the earnings report the stock price went down -4.821%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Among the largest hedge funds holding LENZ Therapeutics’s share is Western Standard Llc. It holds LENZ Therapeutics’s shares valued at N/A.
---
LENZ Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (107.95% Upside)
$34.00 (107.95% Upside)
Hedge Fund Trend
Decreased
By 25.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 33.2%
Last 30 Days ▲ 27.1%
Last 30 Days ▲ 27.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.50%
12-Months-Change
Fundamentals
Return on Equity
-51.95%
Trailing 12-Months
Asset Growth
-41.46%
Trailing 12-Months
Company Description
LENZ Therapeutics
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations.
---
LENZ Stock 12 Month Forecast
Average Price Target
$34.00
▲(107.95% Upside)
Technical Analysis
Best Analysts Covering LENZ
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-9.45%
reiterated a buy rating 11 days ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -9.45% per trade.
---